Research Paper Volume 8, Issue 12 pp 3321—3340

Figure 1. Nuclear expression of p65 and its effect on progression-free survival (PFS) in diffuse large B-cell lymphoma (DLBCL) (A) Representative immunohistochemical analysis (IHC) and histograms for p65 nuclear expression in DLBCL. The mean expression of nuclear p65 was significantly higher in the germinal center B-cell–like (GCB) subtype than in the activated B-cell–like (ABC) subtype. (B) In overall DLBCL, high p65 nuclear expression (p65^high, ≥50% nuclear expression) was associated with a trend towards worse PFS. In patients with stage I/II DLBCL, p65^high correlated with significantly shorter PFS. In patients with stage III/IV DLBCL, p65^high did not show signficant prognostic impact. (C) p65^high correlate with significantly shorter PFS in patients with stage I/II DLBCL independent of GCB/ABC subtypes. (D) TP53 mutation status was significantly associated with higher RELA mRNA expression. (E) In patients with stage I/II DLBCL, p65^high correlate with significantly shorter PFS independent of TP53 mutation status although more significant in patients with wild-type TP53 (WT-TP53). In patients with mutated TP53 (MUT-TP53) and stage III/IV DLBCL, p65^high was associated with a trend of better PFS.